Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo.
Forty-five patients suffering from intermittent claudication were admitted to a double-blind non-crossover study . Three groups were constituted at r and om and treated for 2 months with either 100 mg suloctidil t.i.d . or 1.5 mg dihydroergotoxine methylate t.i.d . or placebo . From the results of measurements of pain-free walking distance and venous occlusion plethysmography recordings , suloctidil was shown to be active and significantly superior to dehydroergotoxine and placebo : in the two latter groups a decrease in calf blood perfusion after 2 months was also noted . The physician 's overall assessment of response to treatment showed that suloctidil and dihydroergotoxine were significantly superior to placebo , and that suloctidil was significantly better than dihydroergotoxine
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .